Since 2026, as technology stocks have corrected, defensive sectors that were previously overlooked are regaining investor attention. The healthcare sector has been particularly prominent, with several related ETFs expected to leverage this trend for rapid growth.
As of February 5, the healthcare, utilities, and consumer staples sectors have all outperformed the S&P 500 Index year-to-date. Against the backdrop of persistent uncertainty in the U.S. economic outlook, defensive sectors are poised for continued leadership opportunities.
The S&P 500 Index has long served as a market benchmark, driven strongly in recent years by technology and artificial intelligence themes, while the medical sector lagged significantly due to a lack of attention. However, this situation is changing. Currently, market capital is shifting from high-risk speculative assets to high-quality enterprises with stable cash flows, and the medical sector precisely aligns with this investment logic.
In this sector rotation within healthcare, four ETFs warrant close attention, covering diversified investment paths from comprehensive industry coverage to specialized sub-sectors.
The SPDR Select Sector Fund – Health Care (XLV) is a foundational tool for positioning across the entire medical sector. This fund tracks the Health Care Select Sector Index, with a portfolio covering all sub-sectors including pharmaceuticals (37%), medical devices (20%), biotechnology (18%), and healthcare providers (16%). As a pure market-oriented sector allocation choice, XLV offers investors diversified and balanced exposure to the medical field.
The iShares U.S. Healthcare Providers ETF (IHF) focuses on healthcare service institutions such as HMOs, hospitals, clinics, and dental facilities. It tracks the Dow Jones U.S. Select Healthcare Providers Index, covering companies of various sizes within the industry. This sub-sector is significantly influenced by federal Medicare policies. While congressional discussions on premium reductions or cost controls could pose challenges, the current legislative gridlock makes substantial policy changes difficult; persistently high medical costs may instead become a favorable factor for this segment.
The iShares U.S. Medical Devices ETF (IHI) targets the medical equipment manufacturing field, tracking the Dow Jones U.S. Select Medical Equipment Index. Its investments include manufacturers of MRI scanners, prosthetics, pacemakers, X-ray machines, and other devices. Notably, numerous equipment companies are leveraging the AI wave to develop medical robotics. Although most projects remain in early R&D stages with limited clinical application, enterprises are continuously increasing investments in AI-related technologies, which is expected to significantly boost revenue and profit growth in this area.
The SPDR S&P Biotech ETF (XBI) focuses on the drug research and discovery field, tracking the S&P Biotechnology Select Industry Index and holding approximately 150 companies. The biotechnology sector is renowned for high risk and high reward; investing in this ETF requires tolerating greater volatility. However, trends toward deregulation could serve as important catalysts. Streamlined approval processes and reduced administrative barriers will accelerate the pace of new drug launches, promoting faster industry innovation. Additionally, the fund employs an equal-weight allocation strategy, aiding in the diversification of individual stock risks.
In summary, whether opting for comprehensive sector benchmark ETFs or betting on specific tracks such as healthcare services, medical devices, or biotechnology, these four ETFs are well-positioned to seize opportunities in this round of medical sector revaluation. As market preference for defensiveness rebounds, the healthcare industry—characterized by essential demand attributes and innovative momentum—is welcoming a long-awaited allocation window.
